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Background: Low levels of high-density lipoproteins (HDL) are considered an important risk factor for
cardiovascular disease and constitute one of the criteria for the Metabolic Syndrome (MetS). Lifestyle interventions
promoting a low-fat, plant-based eating pattern appear to paradoxically reduce cardiovascular risk but also HDL
levels. This study examined the changes in MetS risk factors, in particular HDL, in a large cohort participating in a
30-day lifestyle intervention that promoted a low-fat, plant-based eating pattern.
Methods: Individuals (n = 5,046; mean age = 57.3 ± 12.9 years; 33.5% men, 66.5% women) participating in a in a
Complete Health Improvement Program (CHIP) lifestyle intervention within the United States were assessed at
baseline and 30 days for changes in body mass index (BMI), blood pressure (BP), lipid profile and fasting plasma
glucose (FPG).
Results: HDL levels decreased by 8.7% (p<0.001) despite significant reductions (p<0.001) in BMI (-3.2%), systolic
BP (-5.2%), diastolic BP (-5.2%), triglycerides (TG; -7.7%), FPG (-6.3%), LDL (-13.0%), total cholesterol (TC, -11.1%),
TC: HDL ratio (-3.2%), and LDL: HDL ratio (-5.3%). While 323 participants classified as having MetS at program entry
no longer had this status after the 30 days, 112 participants acquired the MetS classification as a result of reduction
in their HDL levels.
Conclusions: When people move towards a low-fat, plant-based diet, HDL levels decrease while other indicators of
cardiovascular risk improve. This observation raises questions regarding the value of using HDL levels as a predictor
of cardiovascular risk in populations who do not consume a typical western diet. As HDL is part of the assemblage
of risk factors that constitute MetS, classifying individuals with MetS may not be appropriate in clinical practice or
research when applying lifestyle interventions that promote a plant-based eating pattern.
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Epidemiological studies indicate that low levels of plasma
or serum HDL is an important risk factor in the deve-
lopment of cardiovascular disease (CVD) [1]. Consequen-
tially, the National Cholesterol Education Program has
advocated increasing HDL levels as an important strategy
for the primary prevention of CVD [2]. Lowered HDL has* Correspondence: lillian.kent@avondale.edu.au
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reproduction in any medium, provided the oralso been included as one of the risk factors used to estab-
lish a diagnosis of Metabolic Syndrome (MetS) [3].
Lifestyle interventions that promote a low-fat, plant-
based eating pattern have been shown to reduce HDL
levels [4-8]. Consequentially, it has been suggested that
low-fat, plant-based diets may not be ideal for people suf-
fering CVD [9,10], despite being well established to reduce
other CVD risk factors including body mass, BP, TC and
LDL [4-8]. Furthermore, long-term intervention studies in-
volving low-fat, plant-based diets have even been shown to
regress atherosclerotic plaques [4,7] and reduce cardiacd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ently conflicting observation has led to debate surrounding
the merits of a low-fat, plant-based diet for the manage-
ment of CVD. In a recent review of HDL [11] argued that
lowered HDL level is not associated with increased risk of
coronary heart disease in the absence of other lipid or
non-lipid risk factors.
The purpose of this study was to further explore the
changes in CVD risk factors, especially HDL, in a large co-
hort of individuals participating in a lifestyle intervention
that advocated a low-fat, plant-based eating pattern—the
Complete Health Improvement Program (CHIP). The ef-
fect of these changes on the MetS rubic and the implica-
tions of this for classifying individuals with MetS were
specifically examined.
Methods
The study evaluated the pre- to post-biometric changes
of 5,046 individuals (mean age = 57.3±12.9 years; 33.5%
men, 66.5% women), who self-selected to participate in a
CHIP lifestyle intervention conducted in various locations
throughout the United States. Consent for the study was
obtained from Avondale College of Higher Education Hu-
man Research Ethics Committee (Approval No. 20:10:07).
The CHIP intervention, previously described [5,6,12],
encouraged and supported participants to move towards
a low-fat, plant-based diet ad libitum, with emphasis on
the whole-food consumption of grains, legumes, fruits
and vegetables. Specifically, the program recommended
less than 20% of calories be derived from fat. In addition,
participants were encouraged to consume 2-2.5 litres of
water daily and limit their daily intake of added sugar,
sodium and cholesterol to 40 g, 2,000 mg, and 50 mg
respectively. Furthermore, the program encouraged par-
ticipants to engage in 30 minutes of daily moderate-
intensity physical activity and practice stress management
techniques.
Before participating in the CHIP intervention (baseline)
and then again at 30 days (post-intervention), participants’
height, weight, and BP were taken. In addition, fasting
(12-hour) blood samples were collected by trained phle-
botomists and analysed for TC, LDL, HDL, TG and FPG
levels.
The five risk factors for MetS, as described by the
“harmonized definition” [3] are: central obesity (based on
population specific waist circumference), raised BP (sys-
tolic ≥130 mmHg and/or diastolic ≥ 85 mmHg), elevated
FPG (≥5.5 mmol/L), increased TG (≥1.7 mmol/L), and de-
creased HDL (<1.03 mmol/L in males and <1.3 mmol/L in
females). The study participants were classified as meeting
these criteria at baseline and post-intervention, however,
as waist circumference was not measured in this study,
BMI >30 kg/m2 was used as surrogate for central obesity,
as suggested by the International Diabetes Federation [13].Participants were deemed as having MetS if they met three
or more of the defining criteria [3].
The data were analysed using IBM™ Statistics (version
19) and expressed as mean ± standard deviation. The ex-
tent of changes (baseline to post-intervention) in the MetS
risk factors were assessed using paired t-tests. McNemar
chi square test was used to determine changes from base-
line to post-intervention in the number of participants
who met the five MetS risk factor criteria, as well as the
number who were classified as having the syndrome.
Results
Overall changes
After 30 days, significant mean reductions (p<0.001)
were recorded in all of the five MetS risk factors, includ-
ing HDL, which decreased almost 9% (Table 1).
HDL
The change in HDL, stratified according to baseline
HDL level, is presented in Table 2. Participants with the
highest initial levels of HDL experienced the greatest de-
creases in the 30 days. The decrease in HDL was not as
great as the decrease in LDL and TC (13% and 11%, re-
spectively), resulting in improvements in the TC:HDL
ratio of 3% and the LDL:HDL ratio of 5% (Table 1).
MetS
As shown in Table 3, there was a significant reduction in
the number of participants who met the MetS criteria
for BMI, BP, TG and FPG, but a significant increase in
the number of participants who met the criteria for
HDL.
While 1889 (41.7%) participants entered the program
characterised as having MetS, this was reduced to 1566
(34.6%) following the intervention; a reduction of 323
participants. Two hundred and fifty seven participants
who were not classified as having MetS at program entry
acquired this status at the completion of the interven-
tion, however, 157 of these individuals (61%) only did
so because of reduced HDL levels. For these individuals,
the TC: HDL and LDL: HDL ratios increased signi-
ficantly from baseline to post-intervention (3.56±0.77
versus 4.12±0.87, p<0.001; 2.31±0.71 versus 2.44±0.76,
p=0.006, respectively) as both TC (12%, p<0.001) and
LDL (15%, p<0.001) did not decrease as much as HDL
(21%, p<0.001).
Discussion
The most striking observation of the present study is
that when people move towards a low-fat, plant-based
diet, HDL levels tend to decrease while all other mea-
sures of cardiovascular risk improve. This large study is
the first to highlight the implications of this effect
for MetS classification. Furthermore, the findings raise
Table 1 Mean changes in selected risk factors from baseline to 30 days





% change t statistic p value
Mean SD Mean SD
SBP (mmHg) 4550 133.30 19.08 126.35 16.51 -6.95 -7.39, -6.51 -5.2 31.13 <0.001
DBP (mmHg) 4552 79.83 11.04 75.69 9.89 -4.14 -4.43, -3.85 -5.2 28.22 <0.001
BMI (kg/m2) 4514 31.01 7.30 30.03 7.01 -0.98 -1.01, -0.96 -3.2 78.11 <0.001
TC (mg/dl) 4655 193.55 41.75 172.09 37.83 -21.46 -22.23, -20.69 -11.1 54.73 <0.001
HDL (mg/dl) 4654 54.84 25.76 50.07 23.16 -4.77 -5.03, -4.51 -8.7 36.56 <0.001
LDL (mg/dl) 4550 131.10 62.02 114.00 54.87 -17.10 -17.90, -16.30 -13.0 41.98 <0.001
TG (mg/dl) 4650 143.35 90.02 132.30 74.55 -11.05 -12.80, -9.31 -7.7 12.41 <0.001
FPG (mg/dl) 4587 101.29 28.94 94.86 20.99 -6.43 -6.96, -5.90 -6.3 23.99 <0.001
TC:HDL 4651 4.01 1.48 3.88 1.40 -0.13 -0.15, -0.11 -3.2 12.00 <0.001
LDL:HDL 4548 2.56 1.04 2.43 0.98 -0.14 -0.15, -0.12 -5.3 15.48 <0.001
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for predicting cardiovascular risk, especially among spe-
cific groups such as vegetarian populations.
Further evidence that the cardiovascular risk of the
participants in this study improved despite the trend for
HDL to decrease, is seen in the improvements in the
overall TC: HDL and LDL: HDL ratios. A meta-analysis
of 61 prospective studies with vascular deaths as an
endpoint suggested that the TC: HDL ratio was more
predictive than either HDL or non-HDL cholesterol sub-
fractions, and two times more predictive than TC [14].
However, in the present study, this ratio, as well as the
ratio of LDL: HDL, significantly increased among partic-
ipants who were newly characterised with MetS and low
HDL levels. In addition, there were significant reduc-
tions in the number of participants who met the MetS
criteria for BMI, BP, TG and FPG levels (11-29%), as
compared to the 30% increase in the number of par-
ticipants who meet the HDL criterion. These results
show that in the context of interventions that emphasise
a low-fat, plant-based eating pattern, changes in HDL
levels may be misleading, whether measured as an abso-
lute value or calculated as a ratio of TC or LDL.
The consistently strong inverse association between
low HDL levels and the risk of cardiovascular events ob-
served in epidemiological studies [15,16], has tradition-











<40 1196 1676 525 (<0.001) 33.62 4.64
40-59 2203 2030 48.39 5.53
≥60 1255 942 86.39 29.82transport (RCT), also known as cholesterol efflux [16].
Notwithstanding this role, HDL more recently has been
shown to have many anti-atherogenic properties, which
include anti-inflammatory, anti-apoptotic, nitric oxide
promoting, prostacyclin-stabilizing, and platelet-inhibiting
functions [17,18]. Indeed, it has been postulated that the
anti-inflammatory properties of HDL and its ability to
protect LDL from oxidation may be just as important as
its role in RCT [19].
Despite the documented anti-atherogenic properties of
HDL, there is evidence that questions the relationship
between HDL levels and risk of cardiovascular events,
as many individuals who suffer coronary atherosclerotic
events have normal or even elevated HDL levels [18,20].
Specifically, the Framingham study demonstrated that
more than 40% of cardiac events occurred in men and
women with normal HDL levels [20]. In addition, other
studies have shown that when HDL levels are raised
pharmacologically, the elevated levels do not always cor-
relate with reduced risk of coronary heart disease [21,22].
The result of this study, which suggests that HDL
levels may not be helpful for predicting cardiovascular
risk in individuals consuming a low-fat, plant-based
diet, is supported by other epidemiological and clinical
studies. Over 30 years ago, Connor observed that the
Tarahumara Indians of Mexico, who consumed a largely










32.69 6.95 -0.94 -1.28, -0.59, -0.9% 0.546
44.64 7.83 -3.75 -4.02, -3.48, -7.9% <0.001
76.18 28.53 -10.22 -10.88, -9.56, -11.8% <0.001




Baseline Post-program Improved MetS status* % improvement
(N) (N) (N)
BMI 2228 1951 +277 12.4%
BP 2761 1994 +767 27.8%
FPG 1618 1145 +472 29.2%
TG 1606 1426 +180 11.2%
HDL 2030 2640 - 610 -30.0%
*Number of participants who improved their MetS status during the intervention for each of the five criteria.
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carbohydrate, had very low rates of vascular disease and
blood lipids, including HDL [23]. However, blood lipids,
including HDL, were observed to significantly increase
after only five weeks when their traditional diet was
changed to a Western diet [24]. It was argued that the
increase in HDL was the “normal response to a high-fat
diet” and that low-HDL in concert with low-LDL in a
low-fat diet is associated with a low risk of coronary dis-
ease. Other epidemiological findings also show that indi-
viduals who consume a plant-based diet are at lower risk
of CVD and type 2 diabetes mellitus, despite having
lowered HDL levels [19,25]. In addition, the Lifestyle
Heart Trial [7], which incorporated a plant-based diet
with less than 10% fat, showed a 7.9% improvement in
measured coronary artery percent diameter stenosis after
five years despite a 13% reduction in HDL. Similarly, in-
dividuals with diagnosed CVD and a recommendation
for bypass surgery who participated in the Pritikin resi-
dential program, which recommends a plant-based diet
(10% fat), experienced a 16% reduction in HDL but de-
creases in symptomatic angina [26]. These patients averted
surgery for more than five years after program entry des-
pite sustained lowered HDL levels.
The value of increasing HDL levels has been further
questioned as its range of functions has become better
understood [11,17,18]. With its heterogeneous structure
and subtypes, varying functions are now being demon-
strated [18]. To date, a number of apolipoproteins and
antioxidant enzymes have been identified in the HDL
structure that may explain its anti-inflammatory (e.g.
ApoA-1 and paraoxonase 1) and inflammatory proper-
ties (e.g. ApoA-II and ApoC-III) [16,18,27]. Although
the mechanisms governing HDL inflammatory and anti-
inflammatory ratios are yet to be fully elucidated, these
may at least in part be influenced by the presence of ox-
idized lipids and oxidants, which inhibit or directly
damage the anti-inflammatory molecules on HDL [27].
Noteworthy, antioxidants and phytonutrients abundant
in plant foods may increase the activity of HDL enzymes
or counter the adverse effect of oxidants on apoA-1and/or the pro-inflammatory effect on LDL lipids [28].
Given that people following a low-fat, plant-based diet
typically have lowered levels of serum TC and LDL, the
need for elevated HDL levels may be diminished from
an RCT perspective. Indeed, lifestyle factors have been
shown to influence the subpopulations of HDL.
Additional evidence against the role of HDL in CVD
risk has come from genetic studies, designed to exam-
ine the associations of LDL, HDL and TG with CVD
risk [29,30]. Early studies showed that rare mutations
that encode LCAT (lecithin cholesterol acyl transferase)
and ABCA1 (ATP-binding cassette transporter, also
known as cholesterol efflux regulatory protein (CERP)),
which profoundly reduce HDL levels, were inconsist-
ently associated with CVD risk [29]. Subsequent Men-
delian randomization (MR) analyses examined several
DNA variants that affect HDL levels and found no as-
sociations with major adverse CVD end points and risk
of myocardial infarction [29]. In contrast, genetics vari-
ants that raise LDL levels significantly increased CVD
risk. More recent MR analyses, using carotid intima-
media thickness (CIMT) as a surrogate for atheroscler-
osis, confirmed a strong relationship between LDL and
CIMT, but not with HDL and TG [30].
There is also growing evidence that lifestyle interven-
tions may be able to modulate the inflammatory or anti-
inflammatory properties of HDL. In patients at risk of
CVD, the anti-inflammatory properties of HDL im-
proved following lifestyle modification, despite reduc-
tions in HDL [28]. In another study, the HDL shifted
from pro-inflammatory to anti-inflammatory in obese
men, with MetS, who underwent a three-week interven-
tion involving a low-fat, high- fibre diet and exercise
[19]. More specifically, consumption of saturated fat re-
duces the anti-inflammatory potential of HDL, but con-
sumption of polyunsaturated fat has been shown to
increase it [31]. The regulation and function of HDL ap-
pears more complex than originally thought-- although
high HDL levels are associated with reduced CVD at a
population level, at an individual level HDL function
may be more important than the actual HDL levels [32].
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The findings of this study question the value of using HDL
levels as a predictor of cardiovascular risk, especially in
populations who do not consume a typical Western diet.
The appropriateness of applying standard HDL criteria
to populations that consume a plant-based diet may be
particularly problematic. Finally, characterising individuals
with MetS may not be appropriate in clinical practice or
research when applying lifestyle interventions that promote
a plant-based eating pattern.
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